When does Spectral AI report earnings and why it matters for MDAI stock

Spectral AI reports on 24 Mar 2026 after market close. The print matters because management may update FDA timing, BARDA milestones, revenue growth, and R&D spending, all of which can shift the near-term valuation of MDAI stock.

What is Meyka AI’s outlook for MDAI stock

Meyka AI projects **$2.15** in 12 months for MDAI stock, implying **51.41%** upside versus the **$1.42** close. The forecast is model-based and not a guarantee; investors should weigh execution and FDA risk.

How did the BARDA award affect MDAI stock performance

The $31.70M BARDA award lifted MDAI stock sentiment and liquidity, driving an 18.33% intraday gain and volume of **7,175,859** shares, up from average volume **402,294**. The funding reduces short-term dilution pressure.

What are the main risks investors should monitor in MDAI stock

Key risks for MDAI stock include FDA delays, continued negative EPS, tight liquidity with a current ratio of **0.85**, and dependence on adoption of the DeepView system in a niche burn-care market.

US Stocks

BARDA awards $31.70M: MDAI stock Spectral AI, Inc. (NASDAQ) 19 Mar 2026 outlook

ByDanny Kontos March 20, 2026

MDAI stock jumped after Spectral AI, Inc. won $31.70M in BARDA funding, closing the NASDAQ session at $1.42 on 19 Mar 2026. Volume surged to 7,175,859 shares versus an average of 402,294, signaling heavy investor interest. The company reports earnings on 24 Mar 2026 after the close, a key catalyst that could reset sentiment. We focus on financials, the BARDA impact, trading metrics, and what to watch into the earnings print for MDAI stock.